Northwire Canada EditionTuesday, July 21, 2026
Northwire
LOD 0.280 −5.1% FVL 0.970 +6.6% BAG 0.210 +23.5% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.405 +0.0% PNTR 0.320 +8.5% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.355 +0.0% TOM 0.115 +9.5% ALS 57.05 +0.2% LIO 0.130 −7.1% GEMC 0.020 +0.0% CBA 0.070 +7.7% PUMA 0.110 +0.0% LOD 0.280 −5.1% FVL 0.970 +6.6% BAG 0.210 +23.5% FMN 0.240 +0.0% OMM 0.050 +0.0% VUL 0.405 +0.0% PNTR 0.320 +8.5% SWA 0.035 +0.0% GEN 0.065 +0.0% PAT 0.355 +0.0% TOM 0.115 +9.5% ALS 57.05 +0.2% LIO 0.130 −7.1% GEMC 0.020 +0.0% CBA 0.070 +7.7% PUMA 0.110 +0.0%

← Back to our analysis

Original News Release

Therma Bright expands Venowave sales with Gen-X Med

Mr. Rob Fia reports THERMA BRIGHT EXPANDS RELATIONSHIP WITH DISTRIBUTION PARTNER GEN-X MED FOR VENOWAVE SALES Therma Bright Inc. has signed a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Tex. The partnership was hatched after the initial sale of 200 Venowave VW5 units that targeted patients that had undergone specialized knee surgeries by trained surgeons with expertise in the procedure. Specialized knee surgeries represent a high-value and growing segment of the United States health care market. "We are pleased to partner with Therma Bright in offering the Venowave VW5 to our doctor network," shared Beau Wood, president, Gen-X Med. "We've seen great patient success with the initial 200-unit purchase and anticipate placing additional orders as we ramp up awareness and adoption of this special vascular compression therapy solution." Rob Fia, chief executive officer of Therma Bright, added: "This partnership with Gen-X Med is a strategic step in expanding Venowave's presence into a focused and high-value market segment. We believe the Venowave offers significant advantages for patients and the U.S. health care system by reducing postsurgical complications and costly readmissions, which aligns with our mission to provide innovative and effective medical solutions that improve patient outcomes and create value." According to a November, 2024, press announcement from Straits Research, the global compression therapy market was valued at $4.18-billion in 2024 and is projected to grow to $6.72-billion by 2033, representing a compound annual growth rate (CAGR) of 7.30 per cent from 2025 to 2033. About the Venowave VW5 The Venowave VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the Food and Drug Administration-designated durable medical equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by 64 per cent after just two minutes of use and 88 per cent after 50 minutes, the Venowave is the only Medicare-approved reimbursable mobile mechanical compression system available in the U.S. under its HCPCS code E0683. It provides a comfortable and simple treatment solution to accelerate postoperative recovery while managing pain and swelling. About Gen-X Med Gen-X Med is an Arlington, Texas-based, distributor committed to providing health care professionals with specialized, vetted products and exceptional client care. The company's portfolio includes durable medical equipment (DME) products, with a focus on sourcing and providing the most qualified products and services to meet the needs of its clients. About Therma Bright Inc. Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key health care challenges. We seek Safe Harbor.
View at source ↗